Gevo (NASDAQ: GEVO) and Amyris Biotechnologies (NASDAQ:AMRS) are both small-cap oils/energy companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
This table compares Gevo and Amyris Biotechnologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Gevo and Amyris Biotechnologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Gevo presently has a consensus price target of $12.00, indicating a potential upside of 3,429.41%. Amyris Biotechnologies has a consensus price target of $9.67, indicating a potential upside of 89.54%. Given Gevo’s higher probable upside, analysts plainly believe Gevo is more favorable than Amyris Biotechnologies.
Insider and Institutional Ownership
4.0% of Gevo shares are owned by institutional investors. Comparatively, 19.6% of Amyris Biotechnologies shares are owned by institutional investors. 0.1% of Gevo shares are owned by company insiders. Comparatively, 11.3% of Amyris Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Gevo and Amyris Biotechnologies’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gevo||$27.54 million||0.30||-$24.63 million||($1.61)||-0.21|
|Amyris Biotechnologies||$143.45 million||1.77||-$72.32 million||($3.05)||-1.67|
Gevo has higher earnings, but lower revenue than Amyris Biotechnologies. Amyris Biotechnologies is trading at a lower price-to-earnings ratio than Gevo, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Gevo has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Amyris Biotechnologies has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
Gevo Company Profile
Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks in the United States. It operates through two segments, Gevo, Inc. and Gevo Development/Agri-Energy. The company engages in the research and development, and production of isobutanol; development of its proprietary biocatalysts; production and sale of biojet fuel; and retrofit process of chemicals and biofuels. It is also involved in the production of ethanol, isobutanol, and related products. In addition, the company produces and separates its renewable isobutanol through the Gevo Integrated Fermentation Technology platform. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Amyris Biotechnologies Company Profile
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Receive News & Ratings for Gevo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gevo and related companies with MarketBeat.com's FREE daily email newsletter.